The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient preferences and expectations of systemic therapy in renal cell carcinoma.
 
Dena Battle
Honoraria - EMD Serono; Exelixis; Novartis
Consulting or Advisory Role - Exelixis; Pfizer
Travel, Accommodations, Expenses - EMD Serono; Exelixis; Novartis; Pfizer (I)
Other Relationship - Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Merck; Pfizer/EMD Serono
 
Cristiane Decat Bergerot
No Relationships to Disclose
 
Pavlos Msaouel
Honoraria - Bristol-Myers Squibb; Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Mirati Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Ipsen; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I)
Honoraria - Exelixis; Genentech/Roche; MJH Life Sciences
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
 
Michael D. Staehler
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EMD Serono; EUSA Pharma; Exelixis; Incyte; Ipsen; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Exelixis; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Ipsen; MSD Oncology; Novartis; Pfizer